CRISPR Therapeutics (CRSP) shares have caught investor attention after recent trading, with the stock closing at US$54.09. That move comes alongside solid short term returns over the past week and month.

Looking beyond the latest move, CRISPR Therapeutics shows building short term momentum, with a 7 day share price return of 8.61% and 30 day share price return of 8.40%, set against a 1 year total shareholder return of 22.24% but a weaker 5 year total shareholder return.

If you are interested in other opportunities in this area, it could be a good time to broaden your watchlist with: 40 healthcare AI stocks

So with CRISPR Therapeutics showing solid short term returns, but carrying a mixed longer term track record and ongoing losses, is the current US$54.09 share price an opportunity, or is the market already pricing in future growth?

CRISPR Therapeutics valuation: what does the current price imply?

On Simply Wall St's numbers, CRISPR Therapeutics is trading at $54.09 compared with an estimated future cash flow value of $177.40, which implies a very wide discount. That gap, plus a 69.5% stated discount to fair value, will naturally catch the eye of anyone watching the recent share price move.

The SWS DCF model builds that $177.40 estimate by projecting CRISPR Therapeutics's future cash flows and then discounting them back to today. This approach focuses on what the business could generate over time rather than only near term earnings, which is useful for a company that is currently reporting losses and has revenue of $4.1m.

For a clinical stage biotech like CRISPR Therapeutics, a cash flow based view often matters more than near term profitability, because the commercial impact of its pipeline can be lumpy. The same logic applies here, with the DCF output reflecting expectations for high future revenue growth rather than current net income, although those underlying assumptions can change quickly as trial data and regulatory milestones come through.

Result: DCF Fair value of $177.40 (UNDERVALUED)

However, several risks could challenge this picture, including CRISPR Therapeutics reporting ongoing losses of US$568.534m and its reliance on the successful development of its early stage pipeline.

Another view on CRISPR Therapeutics

While the SWS DCF model points to a fair value of $177.40 for CRISPR Therapeutics, price targets tell a more cautious story. The current $54.09 share price sits at a 54% discount to the average analyst target of $83.52, and analysts are not in close agreement on that figure.

That gap between a wide ranging analyst view and a much higher DCF output raises a simple question for you as an investor: which set of assumptions do you trust more, and why?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out CRISPR Therapeutics for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 45 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

If this CRISPR Therapeutics picture feels finely balanced between concern and optimism, take a closer look at the evidence and form your own view with the 2 key rewards and 2 important warning signs

Looking for more investment ideas beyond CRISPR Therapeutics?

Do not stop with CRISPR Therapeutics alone. Broaden your opportunity set with other stocks that fit clear, disciplined criteria for quality, value and resilience using targeted screeners.

• Target potential mispricings by reviewing companies in the 45 high quality undervalued stocks that combine supportive fundamentals with share prices that may not fully reflect them.
• Strengthen the quality of your watchlist by scanning for companies in the solid balance sheet and fundamentals stocks screener (48 results) that pair financial resilience with consistent balance sheet discipline.
• Aim to get ahead of the crowd by checking the screener containing 19 high quality undiscovered gems before attention shifts and fewer opportunities remain.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.